{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:32:07Z","timestamp":1761895927380},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.beha.2014.07.006","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T17:45:55Z","timestamp":1405705555000},"page":"107-119","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Assessing disease burden in patients with classic MPNs"],"prefix":"10.1016","volume":"27","author":[{"given":"Holly","family":"Geyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2014.07.006_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"BLood."},{"issue":"1","key":"10.1016\/j.beha.2014.07.006_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.beha.2014.07.006_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"9464","key":"10.1016\/j.beha.2014.07.006_bib4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"10.1016\/j.beha.2014.07.006_bib5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A\u00a0unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.beha.2014.07.006_bib6","article-title":"The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): an international trial of 1433 patients with myeloproliferative neoplasms (MPNs)","volume":"116","author":"Scherber","year":"2011","journal-title":"Blood."},{"issue":"6 Suppl.","key":"10.1016\/j.beha.2014.07.006_bib7","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/1097-0142(20010915)92:6+<1684::AID-CNCR1497>3.0.CO;2-Z","article-title":"The role of cytokines in cancer-related fatigue","volume":"92","author":"Kurzrock","year":"2001","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.beha.2014.07.006_bib8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.leukres.2013.04.017","article-title":"Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study","volume":"37","author":"Mesa","year":"2013","journal-title":"Leuk Res"},{"issue":"21","key":"10.1016\/j.beha.2014.07.006_bib9","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1182\/blood.V122.21.4087.4087","article-title":"Insomnia, quality of life and MPN symptom Burden: an analysis by The MPN Quality Of Life International Study Group (MPN-QOL ISG)","volume":"122","author":"Geyer","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2014.07.006_bib10","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1182\/blood.V122.21.4088.4088","article-title":"Sexuality challenges, intimacy, and MPN symptom burden: an analysis by The MPN Quality Of Life International Study Group (MPN-QOL ISG)","volume":"122","author":"Geyer","year":"2013","journal-title":"BLood"},{"issue":"11","key":"10.1016\/j.beha.2014.07.006_bib11","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3324\/haematol.2009.007047","article-title":"The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera","volume":"94","author":"Pieri","year":"2009","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.beha.2014.07.006_bib12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1046\/j.1365-2141.2001.03161.x","article-title":"Pruritus in polycythaemia vera: prevalence, laboratory correlates and management","volume":"115","author":"Diehn","year":"2001","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2014.07.006_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ajh.22215","article-title":"Pruritus in primary myelofibrosis: clinical and laboratory correlates","volume":"87","author":"Vaa","year":"2012","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2014.07.006_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0190-9622(85)70149-1","article-title":"Aquagenic pruritus","volume":"13","author":"Steinman","year":"1985","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.beha.2014.07.006_bib15","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.beha.2014.07.006_bib16","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2014.07.006_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/10428194.2011.619608","article-title":"Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms","volume":"53","author":"Johansson","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.beha.2014.07.006_bib18","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2007-11-121434","article-title":"A\u00a0dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis","volume":"111","author":"Passamonti","year":"2008","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2014.07.006_bib19","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2014.07.006_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"10.1016\/j.beha.2014.07.006_bib21","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2014.07.006_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.beha.2014.07.006_bib23","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"BLood"},{"issue":"4","key":"10.1016\/j.beha.2014.07.006_bib24","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"BLood"},{"issue":"2","key":"10.1016\/j.beha.2014.07.006_bib25","first-page":"73","article-title":"Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia","volume":"23","author":"van Genderen","year":"1994","journal-title":"Presse Med"},{"issue":"3","key":"10.1016\/j.beha.2014.07.006_bib26","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2014.07.006_bib27","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.beha.2014.07.006_bib28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO;2-6","article-title":"Clinical course of essential thrombocythemia in 147 cases","volume":"66","author":"Fenaux","year":"1990","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.beha.2014.07.006_bib29","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/1097-0142(19861201)58:11<2440::AID-CNCR2820581115>3.0.CO;2-Y","article-title":"Essential thrombocythemias. Clinical evolutionary and biological data","volume":"58","author":"Bellucci","year":"1986","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.beha.2014.07.006_bib30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","article-title":"Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients","volume":"85","author":"Cervantes","year":"1991","journal-title":"Acta Haematol"},{"issue":"9","key":"10.1016\/j.beha.2014.07.006_bib31","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia."},{"issue":"5","key":"10.1016\/j.beha.2014.07.006_bib32","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"BLood"},{"issue":"2","key":"10.1016\/j.beha.2014.07.006_bib33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/BF02981937","article-title":"Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients","volume":"73","author":"Okamura","year":"2001","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.beha.2014.07.006_bib34","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"BLood"},{"issue":"9","key":"10.1016\/j.beha.2014.07.006_bib35","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"issue":"33","key":"10.1016\/j.beha.2014.07.006_bib36","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.beha.2014.07.006_bib37","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1002\/cncr.26129","article-title":"Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial","volume":"117","author":"Mesa","year":"2011","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.beha.2014.07.006_bib38","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.beha.2014.07.006_bib39","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.1731.1731","article-title":"The myelofibrosis symptom burden (MF-SB): an international phenotypic cluster analysis of 329 patients","volume":"120","author":"Geyer","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2014.07.006_bib40","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","article-title":"The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory","volume":"85","author":"Mendoza","year":"1999","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.beha.2014.07.006_bib41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.beha.2014.07.006_bib42","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"BLood"},{"issue":"6","key":"10.1016\/j.beha.2014.07.006_bib43","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A\u00a0prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2014.07.006_bib44","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3109\/10428194.2013.784970","article-title":"Significance of cytogenetic abnormalities in patients with polycythemia vera","volume":"54","author":"Sever","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2014.07.006_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.4082.4082","article-title":"Clinical factors predictive of myelofibrotic evolutions in patients with essential thrombocythemia and polycythemia vera","volume":"122","author":"Tiribelli","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2014.07.006_bib46","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ajh.23417","article-title":"Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management","volume":"88","author":"Tefferi","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2014.07.006_bib47","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1182\/blood.V122.21.4072.4072","article-title":"Retrospective analysis of 204 patients with polycythemia VERA: The International Working Group For Myeloproliferative Neoplasm Research and Treatment (IWG-MRT) Prognostic Score Is A Good Predictor Of Survival and Prognosis","volume":"122","author":"Benevolo","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2014.07.006_bib48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/bjh.12117","article-title":"Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients","volume":"160","author":"Bonicelli","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2014.07.006_bib49","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.07.006_bib50","first-page":"273","article-title":"Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: dual serial assessment studies for impact of standard therapeutic approaches in MPN populations (MEASURES and SYMPTOMS trials)","volume":"99","author":"Geyer","year":"2014","journal-title":"Haematologica"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692614000474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692614000474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T11:51:07Z","timestamp":1598097067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692614000474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1521692614000474"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2014.07.006","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing disease burden in patients with classic MPNs","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2014.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}